Please login to the form below

Not currently logged in
Email:
Password:

BMS sells APAC assets

Taisho of Japan has agreed to buy BMS' OTC portfolio in Asia Pacific and its stake in BMSI

US pharma company, Bristol-Myers Squibb (BMS) has agreed to sell its over-the-counter (OTC) assets in Asia Pacific (APAC), excluding China and Japan, to Japanese firm Taisho Pharmaceutical for $310m.

Under the deal, Taisho will acquire certain product registrations, trademarks and related assets of selected pharmaceutical and OTC products sold primarily in Indonesia, Thailand and the Philippines, as well as other Asia Pacific countries. The products include, Tempra, Counterpain, Theragran-M, Engran, Ceetrus and Keri.

The deal also includes BMS' 97.97 per cent stake in PT BMS Indonesia (BMSI) and the land, buildings, product registrations, intellectual property, fixed assets, inventory and other related assets owned by BMSI. Both companies expect the deal to complete in quarter four 2009.

All 126 permanent BMSI employees will transfer to Taisho – subject to their rights under law.

"This planned divesture is a part of BMS' strategic transformation into a more focused next-generation biopharma company that develops and commercialises products that address serious unmet medical needs," said Dieter Weinard, president, intercontinental, BMS.

"The company is looking closely at its geographic and manufacturing footprint to align more closely to the scale and size of a biopharma company," he added.

HSBC acted as exclusive financial adviser to BMS on the deal.

16th September 2009

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Cegedim Health Data

Cegedim Health Data provides Real World Data and Evidence services to enable advancements in patient outcomes. With a data history...

Latest intelligence

Personalised medicine: driving a need for greater diversity in clinical trials
Kate Shaw, Innovative Trials' Founder & CEO, investigates one of the biggest challenges facing clinical research today....
Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...